Clinical Trial Update: Optimal Dose of Acetylsalicylic Acid After Coronary Artery Bypass Grafting [Phase 2, Phase 3]

View source ↗

Summary

This document reports an update on a Phase 2/Phase 3 trial investigating the optimal aspirin (acetylsalicylic acid) dose after coronary artery bypass grafting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Stable Angina

Drugs mentioned

• Aspirin (Aspirin)

Snippet

Sponsor: Karolinska University Hospital | Conditions: Coronary Artery Bypass Surgery, Stable Angina | Phase 2, Phase 3 | Status: COMPLETED